Loring Wolcott & Coolidge Fiduciary Advisors LLP Vertex Pharmaceuticals Inc Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.3 Billion
- Q1 2025
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 694 shares of VRTX stock, worth $313,354. This represents 0.0% of its overall portfolio holdings.
Number of Shares
694
Previous 694
-0.0%
Holding current value
$313,354
Previous $279,000
20.43%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding VRTX
# of Institutions
1,833Shares Held
233MCall Options Held
1.38MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$12.9 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$10.6 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.62 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.56 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.32 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $116B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...